Abstract
Since the discovery of the RNA interference (RNAi) phenomenon, RNAi-based therapies now present a huge potential for the treatment of many diseases, including inflammatory and infectious diseases and cancers. While numerous reports have described the development of small interfering RNA (siRNA) delivery systems for in-vivo applications, only a small number of siRNA-based therapies are currently under clinical development. This is essentially due to the lack of efficient and safe siRNA delivery systems for intravenous administration. However, the delivery of siRNA after local injection could represent an attractive route of administration to limit the issues of toxicity associated with systemic injection. We will describe here the different synthetic vectors which have been developed for the local delivery of siRNA in various organs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
